Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia

NCT05734898 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT05734898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05734898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NKG2D CAR-NK Cell Therapy for the Treatment of Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Lead sponsor
Zhejiang University
Phase
Not applicable
Overall status
Unknown status
Start date
March 31, 2023
Completion date
September 30, 2024
Enrollment
30 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

aml